Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer.

ABSTRACT: Pancreatic cancer is an aggressive malignancy with poor prognosis. Recent advances in chimeric antigen receptor (CAR)-T cell immunotherapy have offered renewed hope. The pivotal factors determining the effectiveness of CAR-T cells in the clinic is the selection of a reliable target and a specific ectodomain of CAR molecule. EpCAM is widely expressed in epithelial tumors, including pancreatic cancer, and is used as a tumor target in clinical trials of CAR-T cell therapy for gastric and colorectal cancers. However, the feasibility of using EpCAM CAR-T cells in pancreatic cancer still needs to be verified. In this work, we reported novel EpCAM CAR-T cells with a fully human single-chain variable fragment and evaluated their cytotoxic effects in a panel of pancreatic adenocarcinoma cell lines,

SUBMITTER: Fan YY 

PROVIDER: S-EPMC12717346 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature